2-<2-Chlor-3-methyl-phenoxy>-propionsaeure | 60187-09-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-<2-Chlor-3-methyl-phenoxy>-propionsaeure
• 英文别名: 2-(2-Chloro-3-methylphenoxy)propanoic acid
• CAS: 60187-09-9
• 化学式: C₁₀H₁₁ClO₃
• 分子量: 214.649
• InChiKey: MKZOFPVNAYMEMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS<br/>[FR] MODULATEURS DE PPARG POUR LE TRAITEMENT DE L'OSTÉOPOROSE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015161108A1

  公开（公告）日：2015-10-22

  The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

  本发明提供了一种治疗进行性骨病的方法，如骨质疏松症、佩吉特病、多发性骨髓瘤或甲状旁腺功能亢进症，包括向患有该病的患者施用有效量的非激动剂PPARG调节剂。
• N-BENZYLINDOLE MODULATORS OF PPARG
  申请人：Kamenecka Theodore Mark

  公开号：US20120309769A1

  公开（公告）日：2012-12-06

  The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), and inhibit kinase-mediated (e.g., cdk5-mediated) phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. Side effects such as significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, can be avoided in the mammal receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

  本发明提供了与PPARG（PPARγ）高亲和力结合的分子实体，并抑制激酶介导的（例如，cdk5介导的）PPARG磷酸化，但不产生PPARG的激动作用。本发明的化合物可用于治疗PPARG在其中起作用的患者的疾病，如糖尿病、胰岛素抵抗、葡萄糖耐量受损、糖尿病前期、高血糖、高胰岛素血症、肥胖或炎症。接受该化合物的哺乳动物可以避免显著的体重增加、水肿、骨骼生长或形成的损害、心脏肥大或其任何组合的副作用。还提供了制备这些化合物的方法、评估本发明化合物作为非激动性PPARG结合化合物的生物测定方法以及药物组合物。
• [EN] ALKANOLAMINE SULFATE WATER CONDITIONERS<br/>[FR] AGENTS DE CONDITIONNEMENT DE L'EAU À BASE DE SULFATE D'ALCANOLAMINE
  申请人：HUNTSMAN PETROCHEMICAL LLC

  公开号：WO2016057170A1

  公开（公告）日：2016-04-14

  Embodiments of the present disclosure include an agricultural composition containing an agriculturally active ingredient and a water conditioning agent. The water conditioning agent is an alkanolammonium sulfate. Embodiments of the present disclosure further include a method of conditioning water while maintaining comparable volatility in an agricultural formulation by adding at least one water conditioning agent to an agriculturally active ingredient, wherein the water conditioning agent comprises at least one alkanolamine sulfate.

  本公开的实施例包括一种农业组合物，其含有农业活性成分和水调节剂。水调节剂是一种烷基醇胺硫酸盐。本公开的实施例还包括一种方法，通过向至少一个农业活性成分添加至少一种水调节剂来调节水质，同时保持农业配方中可比的挥发性，其中所述水调节剂包括至少一种烷基胺硫酸盐。
• Synergistic composition conatining herbicide, organic acid and surfactant
  申请人：multiBIND biotec GmbH

  公开号：EP3092899A1

  公开（公告）日：2016-11-16

  The present invention relates to new, highly efficient synergistic compositions comprising: herbicide, organic acid and detergents or emulgators. Said synergistic composition allows significant reduction of herbicide application rates and reduces herbicide resistance. The invention further relates to the method of treating plant or soil with said composition, to the method of producing said composition and to the use of adjuvant comprising organic acid and detergent for enhancing activity of herbicide.

  本发明涉及新型高效增效组合物，包括：除草剂、有机酸和洗涤剂或润湿剂。所述增效组合物可显著降低除草剂的施用率，并减少除草剂的抗药性。本发明还涉及用所述组合物处理植物或土壤的方法、生产所述组合物的方法以及使用由有机酸和洗涤剂组成的佐剂来增强除草剂的活性。
• PPARG modulators for treatment of osteoporosis
  申请人：The Scripps Research Institute

  公开号：US10016394B2

  公开（公告）日：2018-07-10

  The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

  本发明提供了治疗进行性骨病（如骨质疏松症、帕吉特氏病、多发性骨髓瘤或甲状旁腺功能亢进症）的方法，包括向患病患者施用有效量的非拮抗剂 PPARG 调节剂。